Abstract
Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.
| Original language | English |
|---|---|
| Pages (from-to) | 724-9 |
| Number of pages | 6 |
| Journal | Hospital medicine |
| Volume | 65 |
| Issue number | 12 |
| Publication status | Published - Dec 2004 |
Keywords / Materials (for Non-textual outputs)
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Female
- Forecasting
- Humans
- Postmenopause
- Treatment Outcome